LOXL4 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- LOXL4 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100094
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- LOXL4 antibody Polyclonal Antibodies Primary antibodies
Related genes to: LOXL4 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- LOXL4 NIH gene
- Name:
- lysyl oxidase like 4
- Previous symbol:
- -
- Synonyms:
- FLJ21889, LOXC
- Chromosome:
- 10q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-11-14
- Date modifiied:
- 2016-10-05
Related products to: LOXL4 antibody Polyclonal Antibodies Primary antibodies
Related articles to: LOXL4 antibody Polyclonal Antibodies Primary antibodies
- The recent inclusion of the Merlin clinicopathologic-gene expression profile (CP-GEP) assay in the National Comprehensive Cancer Network (NCCN) Melanoma Guidelines represents an important milestone in the clinical integration of molecular testing for cutaneous melanoma. Unlike earlier melanoma gene expression profile (GEP) assays, which focused primarily on prognostic risk stratification, CP-GEP was specifically developed to predict sentinel lymph node (SLN) metastasis risk by identifying early metastatic competence within primary melanomas, with additional prognostic utility. This review discusses the biological evidence supporting CP-GEP and examines how unbiased transcriptomic discovery converged with established insights from cancer cell biology, integrin signaling, focal adhesions, and extracellular matrix (ECM) remodeling to shape its conceptual framework. We further discuss how CP-GEP captures a transformation-associated biological state centered on an integrin- and TGF-β-dependent signaling axis (ITGB3, TGFBR1) that promotes pericellular proteolysis and ECM remodeling (PLAT, SERPINE2, LOXL4), inflammatory and angiogenic signaling (CXCL8, GDF15), and melanocytic lineage identity (MLANA). Collectively, these genes identify a dissemination-competent phenotype that is detectable within primary tumors before clinically apparent metastasis. Overall, the biological framework supporting CP-GEP reinforces the concept that altered adhesion signaling and ECM remodeling are central drivers of early melanoma metastasis and represent clinically actionable biomarkers for individualized melanoma management. - Source: PubMed
Publication date: 2026/08/03
Jing Frank ZMeves Alexander - Hepatocellular carcinoma (HCC) typically progresses within a fibrotic, collagen-rich microenvironment where extracellular matrix (ECM) remodeling critically dictates tumor malignancy. However, the cell-type-specific contributions of the lysyl oxidase (LOX) family to this remodeling remain poorly understood. In this study, we conducted an integrative transcriptomic analysis of the LOX gene family (LOX, LOXL1-4) in HCC. Bulk RNA-seq analysis revealed that LOX, LOXL2, and LOXL4 were significantly upregulated in tumors and correlated with advanced pathological stages and poor prognosis. Single-cell RNA-seq (scRNA-seq) analysis delineated distinct expression landscapes: LOX and LOXL4 were enriched in malignant cells, while LOXL2 was predominantly expressed in fibroblasts and endothelial cells. Notably, we identified a discrete LOXL2⁺ fibroblast subset characterized by transcriptomic programs associated with ECM remodeling, contractility, angiogenesis, and hypoxia. A signature derived from LOXL2⁺ fibroblasts was significantly associated with inferior overall survival and enhanced epithelial-mesenchymal transition (EMT) activity in the TCGA-LIHC cohort. Intercellular signaling analysis (CellChat) demonstrated that LOXL2⁺ fibroblasts engage in robust crosstalk with malignant cells via collagen/periostin-integrin signaling axes. Finally, STIP1 was identified through LASSO and random survival forest models as a critical prognostic effector within the LOXL2⁺ fibroblast program. Our findings establish LOXL2⁺ fibroblasts as a pivotal stromal subset driving malignant remodeling and provide potential therapeutic targets for HCC. - Source: PubMed
Publication date: 2026/05/30
Chen HaijunZhu LujianLin JunmeiYe XuxingHua HongjunYang ChaoWang Xiaobo - Radiotherapy (RT) resistance in glioma is closely linked to abnormal JAK/STAT signaling, but its upstream drivers are unclear. This study investigates the role of lysyl oxidase-like 4 (LOXL4) in this process. - Source: PubMed
Publication date: 2026/05/14
Du GuoDing ZhaojunHou JianxunSu QiuyuLi QinhongXia XiaohuiYang Zhao - Glioblastoma (GBM) is the most common malignant brain tumor, and effective therapeutic strategies remain scarce. Therefore, the study aims to screen biomarkers to reveal the molecular mechanisms of cancer stem cells (CSCs) and disulfidptosis in GBM therapy. - Source: PubMed
Publication date: 2026/02/27
Tang DangRen ZhongkunGao BiboLong Jiang - Spondylolisthesis is a spinal disorder characterized by abnormal vertebral displacement, primarily affecting the lumbar region. Understanding the genetic factors underlying its progression is critical. - Source: PubMed
Publication date: 2026/02/04
Wang HuiNiu PengYang XiuLin XinLi JinquanWu GuangyinSun XiaotangHuang JianghuLin Feiyue